Literature DB >> 27837671

d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder.

A S de Leeuw1, H J G M van Megen2, R S Kahn3, H G M Westenberg3.   

Abstract

BACKGROUND: Preliminary studies have shown that the addition of the partial NMDA-agonist d-cycloserine (DCS) might be promising in enhancing the results of exposure therapy in obsessive-compulsive disorder (OCD). We examined the effect of DCS addition to exposure therapy in a somewhat larger sample of OCD patients with special attention to subgroups, because of the heterogeneity of OCD.
METHODS: A randomized, double-blind, placebo controlled trial was conducted in 39 patients with OCD. Patients received 6 guided exposure sessions, once a week. One hour before each session 125mg DCS or placebo was administered.
RESULTS: Scores on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) declined more in the DCS group than in the placebo group, but the difference did not reach statistical significance (P=0.076, partial η2=0.13). Response percentages also did not differ between the DCS and the placebo group (37% and 15% respectively). In the 'cleaning/contamination' subgroup a significant effect was found in favour of DCS (P=0.033, partial η2=0.297).
CONCLUSIONS: The results of this study did not support the application of DCS to exposure therapy in OCD. Some specific aspects need further investigation: efficacy of DCS in a larger 'cleaning/contamination' (sub-)group, DCS addition only after successful sessions, interaction with antidepressants. Copyright Â
© 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Exposure and response prevention; Obsessive-compulsive disorder; d-cycloserine

Mesh:

Substances:

Year:  2016        PMID: 27837671     DOI: 10.1016/j.eurpsy.2016.06.011

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  6 in total

1.  Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.

Authors:  David Rosenfield; Jasper A J Smits; Stefan G Hofmann; David Mataix-Cols; Lorena Fernández de la Cruz; Erik Andersson; Christian Rück; Benedetta Monzani; Ana Pérez-Vigil; Paolo Frumento; Michael Davis; Rianne A de Kleine; JoAnn Difede; Boadie W Dunlop; Lara J Farrell; Daniel Geller; Maryrose Gerardi; Adam J Guastella; Gert-Jan Hendriks; Matt G Kushner; Francis S Lee; Eric J Lenze; Cheri A Levinson; Harry McConnell; Jens Plag; Mark H Pollack; Kerry J Ressler; Thomas L Rodebaugh; Barbara O Rothbaum; Eric A Storch; Andreas Ströhle; Candyce D Tart; David F Tolin; Agnes van Minnen; Allison M Waters; Carl F Weems; Sabine Wilhelm; Katarzyna Wyka; Margaret Altemus; Page Anderson; Judith Cukor; Claudia Finck; Gary R Geffken; Fabian Golfels; Wayne K Goodman; Cassidy A Gutner; Isobel Heyman; Tanja Jovanovic; Adam B Lewin; Joseph P McNamara; Tanya K Murphy; Seth Norrholm; Paul Thuras; Cynthia Turner; Michael W Otto
Journal:  J Anxiety Disord       Date:  2019-09-23

Review 2.  Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.

Authors:  Zoya Marinova; De-Maw Chuang; Naomi Fineberg
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 3.  Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).

Authors:  Antonio Del Casale; Serena Sorice; Alessio Padovano; Maurizio Simmaco; Stefano Ferracuti; Dorian A Lamis; Chiara Rapinesi; Gabriele Sani; Paolo Girardi; Georgios D Kotzalidis; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

4.  The effectiveness of exposure and response prevention combined with pharmacotherapy for obsessive-compulsive disorder: A systematic review and meta-analysis.

Authors:  Lingyun Mao; Maorong Hu; Lan Luo; Yunhong Wu; Zihang Lu; Jingzhi Zou
Journal:  Front Psychiatry       Date:  2022-09-15       Impact factor: 5.435

Review 5.  Placebo Effect in Obsessive-Compulsive Disorder (OCD). Placebo Response and Placebo Responders in OCD: The Trend Over Time.

Authors:  Georgios D Kotzalidis; Antonio Del Casale; Maurizio Simmaco; Lucia Pancheri; Roberto Brugnoli; Marco Paolini; Ida Gualtieri; Stefano Ferracuti; Valeria Savoja; Ilaria Cuomo; Lavinia De Chiara; Alessio Mosca; Gabriele Sani; Paolo Girardi; Maurizio Pompili; Chiara Rapinesi
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

6.  Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder: A Randomized Clinical Trial.

Authors:  Gerd Kvale; Bjarne Hansen; Kristen Hagen; Jonathan S Abramowitz; Tore Børtveit; Michelle G Craske; Martin E Franklin; Svein Haseth; Joseph A Himle; Sigurd Hystad; Unn Beate Kristensen; Gunvor Launes; Anders Lund; Stian Solem; Lars-Göran Öst
Journal:  JAMA Netw Open       Date:  2020-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.